Liliya V Frolova

Prof. Liliya V Frolova

Purdue University Fort Wayne
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Alexander Victorovich AksenovAlexander Victorovich Aksenov
Alexander Victorovich Aksenov
ASAlexander N. Smirnov
Alexander N. Smirnov
IMIgor V. Magedov
Igor V. Magedov
MRMary R. Reisenauer
Mary R. Reisenauer
NANicolai A. Aksenov
Nicolai A. Aksenov
LFLiliya V Frolova
Liliya V Frolova

8 August 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LFLiliya V Frolova
Liliya V Frolova
IMIgor V. Magedov
Igor V. Magedov
ARAnntherese E. Romero
Anntherese E. Romero
MKMenuka Karki
Menuka Karki
IOIsaiah Otero
Isaiah Otero
Alexander KorneinkoAlexander Korneinko
Alexander Korneinko

18 March 2014 in ChemMedChem
Verified
Journal Article
Open access
PDF file
RSRobert Scott
Robert Scott
MKMenuka Karki
Menuka Karki
MRMary R. Reisenauer
Mary R. Reisenauer
RRRoberta Rodrigues
Roberta Rodrigues
RDRamesh Dasari
Ramesh Dasari
Alexander KorneinkoAlexander Korneinko
Alexander Korneinko
C2‐aryl‐ and C2‐alkyl‐7‐deazahypoxanthines as analogues of marine alkaloid rigidins were prepared utilizing novel synthetic methods developed for the construction of the pyrrolo[2,3‐d]pyrimidine ring system. The new compounds exhibited sub‐micromolar to nanomolar antiproliferative potencies against a panel of cell lines including in vitro models for drug‐resistant tumors, such as glioblastoma, melanoma and non‐small‐cell lung cancer. A selected representative C2‐methyl‐7‐deazahypoxanthine was found to inhibit microtubule dynamics in cancer cells, lending evidence for tubulin targeting as a mode of action for these compounds in cancer cells. The results of the docking studies utilizing the colchicine site on β‐tubulin were consistent with the observed structure–activity relationship data, including an important finding that derivatization at C2 with linear alkyl groups leads to the retention of activity, thus permitting the attachment of a biotin‐containing linker for the subsequent proteomics assays. Because many microtubule‐targeting compounds are successfully used to fight cancer in the clinic, the reported antitubulin rigidin analogues have significant potential as new anticancer agents.

1 September 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SHSean Henry
Sean Henry
RKRia Kidner
Ria Kidner
MRMary R. Reisenauer
Mary R. Reisenauer
IMIgor V. Magedov
Igor V. Magedov
RKRobert Kiss
Robert Kiss
LFLiliya V Frolova
Liliya V Frolova

7 December 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DMDerek C. Medellin
Derek C. Medellin
QZQiong Zhou
Qiong Zhou
RSRobert Scott
Robert Scott
RHR. Matthew Hill
R. Matthew Hill
SFSarah K. Frail
Sarah K. Frail
Alexander KorneinkoAlexander Korneinko
Alexander Korneinko

22 December 2021 in Molbank
Verified
Journal Article
Open access
PDF file
DADmitrii Aksenov
Dmitrii Aksenov
Alexander Victorovich AksenovAlexander Victorovich Aksenov
Alexander Victorovich Aksenov
LPLidiya A. Prityko
Lidiya A. Prityko
NANicolai A. Aksenov
Nicolai A. Aksenov
LFLiliya V Frolova
Liliya V Frolova
MRMichael Rubin
Michael Rubin
2-Aryl-2-(3-indolyl)acetohydroxamic acids demonstrate promising antitumor activity, but quickly metabolize in vivo via glucuronidation of hydroxamic acid residue. In an attempt to improve their pharmacokinetics, methyl esters were synthesized via a newly developed protocol for chemoselective mono-methylation of hydroxamic acids. The cytotoxicity of these derivatives against the HeLa cell line was evaluated and found to be inferior compared to the parent lead compounds.